Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Climb Bio, Inc. Director's Dealing 2024

Jun 21, 2024

33982_dirs_2024-06-21_621402bd-71c6-40b5-906a-b5f41dfe18ef.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Eliem Therapeutics, Inc. (ELYM)
CIK: 0001768446
Period of Report: 2024-06-18

Reporting Person: Pimblett Emily (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-06-18 Common Stock M 5000 Acquired 5000 Direct
2024-06-20 Common Stock S 1245 $7.2145 Disposed 3755 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-06-18 Restricted Stock Units $ M 5000 Disposed Common Stock (5000) Direct

Footnotes

F1: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.

F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.

F3: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.